Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products.
about
Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients.The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia.Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp.Phase I study of sunitinib and erlotinib in advanced nonsquamous non-small cell lung cancerEfficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes.Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients.United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignanciesPharmacologic modulation strategies to reduce dose requirements of anticancer therapy while preserving clinical efficacy.Lipid-associated oral delivery: Mechanisms and analysis of oral absorption enhancement.Review and analysis of FDA approved drugs using lipid-based formulations.Safety, tolerability, and pharmacokinetics of amuvatinib from three phase 1 clinical studies in healthy volunteers.Clinical trial simulation to evaluate population pharmacokinetics and food effect: capturing abiraterone and nilotinib exposures.Are drug labels static or dynamic?Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk-Benefit Approach.To Take or Not to Take With Meals? Unraveling Issues Related to Food Effects Labeling for Oral Antineoplastic Drugs.The Role of Clinical Pharmacology in Oncology Dose Selection: Advances and Opportunities in Personalized Medicine.Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.A Phase 1, Randomized, Single-Dose Crossover Pharmacokinetic Study to Investigate the Effect of Food Intake on Absorption of Orteronel (TAK-700) in Healthy Male Subjects.Effects of meal type on the oral bioavailability of the ALK inhibitor ceritinib in healthy adult subjects.Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer.Food Effect on Oral Bioavailability: Old and New Questions.Playing Russian roulette with tyrosine kinase inhibitors.Effect of Food and Esomeprazole on the Pharmacokinetics of Alectinib, a Highly Selective ALK Inhibitor, in Healthy Subjects.Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects.
P2860
Q33434141-A74BF60D-B30D-41A6-8B7B-BE2B6476653FQ35542196-00259C8B-AA3F-4DFD-8911-A954B1125427Q35567942-B7A6A8CA-972C-4E75-A48C-D96E7A20B466Q35852614-F02C8903-3FBF-4E2B-9C2D-19AAC9426507Q35986273-C59D6603-034C-428A-AB44-61629B20F899Q36799188-4AB76772-1040-468B-82B9-0096CBD72FB2Q36906428-AB5B67D3-F924-4D9F-9512-84B104F5269DQ37142970-813C8EE2-7EC3-4EF6-848D-6A752A296F31Q38024126-4F9377B3-7499-44B7-990F-ABF7AAA8AF42Q38926514-2D328A56-B5F9-4483-8A4F-EF7B6C231C04Q39411779-5D15EF45-1719-435D-9F12-8546ACB1DEFCQ39650482-4694A1C6-30EE-4C07-B407-BDDA02B5B37DQ42109132-DDFFE675-1683-4BBA-AC21-79397FAC13DFQ47735995-35CF7EC1-B5F2-4D9B-A02F-CFFC2E1C743DQ47969034-7C465E9A-13F0-4B5C-AB34-5D88760FC06FQ49350350-377CC418-6593-41F0-9529-42691FD8EADBQ50045470-527E77AC-2130-4BB2-9565-905387B81742Q51244133-16F57854-1CF6-4348-B6B7-844A4889DDE8Q51284848-C5CD8762-70CF-4E43-9828-8ED153955C45Q51298596-B3BA5749-8577-4D13-A24E-8457934D2B1CQ51301052-70804308-EB9A-456E-A478-E83C02A40E2BQ53370868-EC6966EA-3D25-489F-82EA-24ACF7867EFEQ54455013-A9E94F1F-AF16-4F18-B885-3658901160E4Q55017122-239C6697-005D-4E39-97D8-C8211D93CB6EQ55060584-3015DF25-0E3D-491E-BF74-F50E20AB4DFE
P2860
Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Inconsistent labeling of food ...... ogy and non-oncology products.
@ast
Inconsistent labeling of food ...... ogy and non-oncology products.
@en
Inconsistent labeling of food ...... ogy and non-oncology products.
@nl
type
label
Inconsistent labeling of food ...... ogy and non-oncology products.
@ast
Inconsistent labeling of food ...... ogy and non-oncology products.
@en
Inconsistent labeling of food ...... ogy and non-oncology products.
@nl
prefLabel
Inconsistent labeling of food ...... ogy and non-oncology products.
@ast
Inconsistent labeling of food ...... ogy and non-oncology products.
@en
Inconsistent labeling of food ...... ogy and non-oncology products.
@nl
P2860
P1476
Inconsistent labeling of food ...... ogy and non-oncology products.
@en
P2093
Soonmo Peter Kang
P2860
P304
P356
10.1158/1078-0432.CCR-10-0663
P407
P577
2010-08-24T00:00:00Z